Tadalafil indications and usage: Difference between revisions

Revision as of 22:15, 7 February 2014

Tadalafil
ADCIRCA (tadalafil) tablet ^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

For patient information, click here

^[1]

@@ Line 1: / Line 1: @@
 __NOTOC__
-{{Nitroglycerin}}
+{{Tadalafil}}
 {{CMG}}; {{AE}} {{PB}}
-'''''For patient information, click <u>[[Nitroglycerin tablet (patient information)|here]]'''''</u>
+'''''For patient information, click <u>[[Tadalafil tablet (patient information)|here]]'''''</u>